Antireflux metallic biliary stents: Where do we stand?

Christine Boumitri, MD

Division of Gastroenterology and Hepatology, University of Missouri, Columbia, Missouri, USA

Monica Gaidhane, MD, MPH, Michel Kahaleh, MD, FASGE

Division of Gastroenterology and Hepatology, Weill Cornell Medical College, New York, New York, USA

Ampulla of Vater is a tricky location to insert a biliary stent as it can disrupt the function of the sphincter of Oddi, preventing reflux of duodenal contents.                              Therefore, it might increase the risk of cholangitis, induced by post-ERCP.  In order to resolve concern of the reflux, EGIS M-valve stent is invented.                                    Overall reflux of barium was significantly lower in ARVMS with M-valve stents than cSEMS group with conventional stents (7.7% vs 100%, P < .001).                                      The patency of the M-valve stents was significantly longer compared with conventional SEMSs. (407 vs 220 days, P = .013).                                                                              (Boumitri, C., Gaidhane, M., & Kahaleh, M. (2016). Gastrointestinal Endoscopy, 83(2), 413–415)

Here are the following articles:

  1. Antireflux metallic biliary stents: Where do we stand?

2.  M-valve’s original article